Diabetes, Vol 49, Issue 6 999-1005, Copyright © 2000 by American Diabetes Association

ARTICLES

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

P Kurtzhals, L Schaffer, A Sorensen, C Kristensen, I Jonassen, C Schmid and T Trub
Health Care Discovery, Novo Nordisk, Bagsvaerd, Denmark. pkur@novo.dk

In recent years, analogs of human insulin have been engineered with the aim of improving therapy for people with diabetes. To ensure that the safety profile of the human hormone is not compromised by the molecular modifications, the toxico-pharmacological properties of insulin analogs should be carefully monitored. In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(epsilon-tetradecanoyl), desB30 human insulin], and reference insulin analogs. Receptor affinities were measured using purified human receptors, insulin receptor dissociation rates were determined using Chinese hamster ovary cells overexpressing the human insulin receptor, metabolic potencies were evaluated using primary mouse adipocytes, and mitogenic potencies were determined in human osteosarcoma cells. Metabolic potencies correlated well with insulin receptor affinities. Mitogenic potencies in general correlated better with IGF-I receptor affinities than with insulin receptor off-rates. The 2 rapid-acting insulin analogs aspart and lispro resembled human insulin on all parameters, except for a slightly elevated IGF-I receptor affinity of lispro. In contrast, the 2 long-acting insulin analogs, glargine and detemir, differed significantly from human insulin. The combination of the B31B32diArg and A21Gly substitutions provided insulin glargine with a 6- to 8-fold increased IGF-I receptor affinity and mitogenic potency compared with human insulin. The attachment of a fatty acid chain to LysB29 provided insulin detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies. The safety implications of the increased growth-stimulating potential of insulin glargine are unclear. The reduced in vitro potency of insulin detemir might explain why this analog is not as effective on a molar basis as human insulin in humans.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Porcellati, P. Rossetti, N. R. Busciantella, S. Marzotti, P. Lucidi, S. Luzio, D. R. Owens, G. B. Bolli, and C. G. Fanelli Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study Diabetes Care, October 1, 2007; 30(10): 2447 - 2452. [Abstract] [Full Text] [PDF]

				L. Jovanovic and D. J. Pettitt Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S220 - S224. [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				J-W Chen, J Frystyk, T Lauritzen, and J S Christiansen Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes Eur. J. Endocrinol., December 1, 2005; 153(6): 907 - 913. [Abstract] [Full Text] [PDF]

				T. P. Ciaraldi, S. A. Phillips, L. Carter, V. Aroda, S. Mudaliar, and R. R. Henry Effects of the Rapid-Acting Insulin Analog Glulisine on Cultured Human Skeletal Muscle Cells: Comparisons with Insulin and Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5551 - 5558. [Abstract] [Full Text] [PDF]

				J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, and T. R. Pieber Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus Arch Intern Med, June 27, 2005; 165(12): 1337 - 1344. [Abstract] [Full Text] [PDF]

				M. A. Bethel and M. N. Feinglos Basal Insulin Therapy in Type 2 Diabetes J Am Board Fam Med, May 1, 2005; 18(3): 199 - 204. [Abstract] [Full Text] [PDF]

				A. Mohn, M. Marcovecchio, F. Chiarelli, M. C. Haffner, M. P. Kufner, B. O. Boehm, and I. B. Hirsch Insulin Analogues N. Engl. J. Med., April 28, 2005; 352(17): 1822 - 1824. [Full Text] [PDF]

				A. M. Hennige, R. Lehmann, C. Weigert, K. Moeschel, M. Schauble, E. Metzinger, R. Lammers, and H.-U. Haring Insulin Glulisine: Insulin Receptor Signaling Characteristics In Vivo Diabetes, February 1, 2005; 54(2): 361 - 366. [Abstract] [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				A. Duttaroy, P. Kanakaraj, B. L. Osborn, H. Schneider, O. K. Pickeral, C. Chen, G. Zhang, S. Kaithamana, M. Singh, R. Schulingkamp, et al. Development of a Long-Acting Insulin Analog Using Albumin Fusion Technology Diabetes, January 1, 2005; 54(1): 251 - 258. [Abstract] [Full Text] [PDF]

				S. I. Chisalita and H. J. Arnqvist Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E896 - E901. [Abstract] [Full Text] [PDF]

				R. G. Bretzel, S. Arnolds, J. Medding, and T. Linn A Direct Efficacy and Safety Comparison of Insulin Aspart, Human Soluble Insulin, and Human Premix Insulin (70/30) in Patients With Type 2 Diabetes Diabetes Care, May 1, 2004; 27(5): 1023 - 1027. [Abstract] [Full Text] [PDF]

				J. Westerbacka, R. Bergholm, M. Tiikkainen, and H. Yki-Jarvinen Glargine and Regular Human Insulin Similarly Acutely Enhance Endothelium-Dependent Vasodilatation in Normal Subjects Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 320 - 324. [Abstract] [Full Text]

				S. Vehkavaara and H. Yki-Jarvinen 3.5 Years of Insulin Therapy With Insulin Glargine Improves In Vivo Endothelial Function in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 325 - 330. [Abstract] [Full Text]

				I. Rakatzi, S. Ramrath, D. Ledwig, O. Dransfeld, T. Bartels, G. Seipke, and J. Eckel A Novel Insulin Analog With Unique Properties: LysB3,GluB29 Insulin Induces Prominent Activation of Insulin Receptor Substrate 2, but Marginal Phosphorylation of Insulin Receptor Substrate 1 Diabetes, September 1, 2003; 52(9): 2227 - 2238. [Abstract] [Full Text] [PDF]

				J.-W. Chen, T. Ledet, H. Orskov, N. Jessen, S. Lund, J. Whittaker, P. De Meyts, M. B. Larsen, J. S. Christiansen, and J. Frystyk A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1149 - E1155. [Abstract] [Full Text] [PDF]

				P. Vague, J.-L. Selam, S. Skeie, I. De Leeuw, J. W.F. Elte, H. Haahr, A. Kristensen, and E. Draeger Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart Diabetes Care, March 1, 2003; 26(3): 590 - 596. [Abstract] [Full Text] [PDF]

				N. Younis, H. Soran, and D. Bowen-Jones Insulin glargine: a new basal insulin analogue QJM, November 1, 2002; 95(11): 757 - 761. [Full Text] [PDF]

				J. Plank, A. Wutte, G. Brunner, A. Siebenhofer, B. Semlitsch, R. Sommer, S. Hirschberger, and T. R. Pieber A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients With Type 1 Diabetes Diabetes Care, November 1, 2002; 25(11): 2053 - 2057. [Abstract] [Full Text] [PDF]

				T. Lindstrom, C. A. Hedman, and H. J. Arnqvist Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs Diabetes Care, June 1, 2002; 25(6): 1049 - 1054. [Abstract] [Full Text] [PDF]

				J. T. Devlin, L. Hothersall, and J.L. Wilkis Use of Insulin Glargine During Pregnancy in a Type 1 Diabetic Woman Diabetes Care, June 1, 2002; 25(6): 1095 - 1096. [Full Text] [PDF]

				T. Kjeldsen, S. Ludvigsen, I. Diers, P. Balschmidt, A. R. Sorensen, and N. C. Kaarsholm Engineering-enhanced Protein Secretory Expression in Yeast with Application to Insulin J. Biol. Chem., May 17, 2002; 277(21): 18245 - 18248. [Abstract] [Full Text] [PDF]

				K. L. Herbst and I. B. Hirsch Insulin Strategies for Primary Care Providers Clin. Diabetes, January 1, 2002; 20(1): 11 - 17. [Abstract] [Full Text] [PDF]

				T. P. Ciaraldi, L. Carter, G. Seipke, S. Mudaliar, and R. R. Henry Effects of the Long-Acting Insulin Analog Insulin Glargine on Cultured Human Skeletal Muscle Cells: Comparisons to Insulin and IGF-I J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5838 - 5847. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				C. A. Hedman, T. Lindström, and H. J. Arnqvist Direct Comparison of Insulin Lispro and Aspart Shows Small Differences in Plasma Insulin Profiles After Subcutaneous Injection in Type 1 Diabetes Diabetes Care, June 1, 2001; 24(6): 1120 - 1121. [Full Text]

				J. Fawcett, F. G. Hamel, R. G. Bennett, Z. Vajo, and W. C. Duckworth Insulin and Analogue Effects on Protein Degradation in Different Cell Types. DISSOCIATION BETWEEN BINDING AND ACTIVITY J. Biol. Chem., April 6, 2001; 276(15): 11552 - 11558. [Abstract] [Full Text] [PDF]